

## Araclon Biotech to highlight clinical data on its Alzheimer's vaccine at upcoming scientific conferences

- *Presentations on clinical progress of Araclon's ABvac40 program include final phase 2 study results in late-breaking presentation at CTAD 2023*
- *Araclon's previously reported ABvac40 interim phase 2 findings demonstrated promising safety, tolerability and a robust immune response in Alzheimer's patients*

**Zaragoza, Spain, October 11, 2023** – Araclon Biotech, a Grifols Group company dedicated to the research and development of therapies and diagnostic methods applied to neurodegenerative diseases, today announced participation at upcoming scientific conferences to present clinical data from studies of its Alzheimer's vaccine candidate, ABvac40 ([NCT03461276](https://clinicaltrials.gov/ct2/show/study/NCT03461276)), for treatment of patients with Alzheimer's disease (AD).

This will include a late-breaking presentation of previously unreleased final results from Araclon's phase 2 study of ABvac40 at the Clinical Trials on Alzheimer's Disease 2023 (CTAD) conference, in addition to discussions of the ABvac40 program at the 2023 European Alzheimer's Disease Consortium (EADC) and the Annual Meeting of the Spanish Society of Neurology 2023 (SEN).

ABvac40 is a clinical vaccine developed to specifically target the A $\beta$ 40 peptide, a key pathological feature associated with AD. In addition, deposition of A $\beta$ 40 in the brain plays a primary role in cerebral amyloid angiopathy, a highly prevalent condition among AD patients.

Based on its phase 2 interim findings presented at the 2022 International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (AD/PD™ 2022), ABvac40 demonstrated promising safety, tolerability and a robust immune response in patients with amnesic mild cognitive impairment (aMCI) or very mild AD (vm-AD). These results were confirmed with the complete interim readout of the study presented at the 2023 Alzheimer's Association International Conference (AAIC 2023).

Upcoming presentation details can be found below.

## Presentation Details:

**Event:** European Alzheimer's Disease Consortium Meeting 2023  
**Location:** Aula Benvenuto, 5<sup>th</sup> Floor, University of Genoa, Genova, Italy  
**Date & Time:** October 12, 2023, 4:15pm CET  
**Presentation Title:** ABvac40: A novel Alzheimer vaccine against A $\beta$ 40 peptide

**Event:** Clinical Trials on Alzheimer's Disease 2023 Conference  
**Location:** Grand Ballroom AB – Floor 2 Mezzanine Level, Boston Park Plaza, Boston, Massachusetts  
**Date & Time:** October 24, 2023, 6:20pm ET  
**Late-breaking Presentation Title:** Safety, immunogenicity, clinical efficacy and biomarkers of ABvac40, an active vaccine anti-A $\beta$ 40 in patients with amnesic mild cognitive impairment of very mild Alzheimer's disease: final results of a phase 2 randomized study

**Event:** 75<sup>th</sup> Annual Meeting of the Spanish Society of Neurology  
**Location:** Recatí A Room, Hotel Sercotel Sorolla, Valencia, Spain  
**Date & Time:** November 1, 2023, 1:30pm – 3:30pm CET  
**Seminar Title:** Araclon Biotech: Advances in early diagnosis and treatment of Alzheimer's disease

## About Araclon Biotech

Araclon Biotech specializes in researching and developing therapies and diagnostic methods for Alzheimer's disease (AD) and other neurodegenerative diseases. The company, in which Grifols holds a stake of almost 76%, focuses on two research areas: the early diagnosis of AD by means of detecting amyloid-beta peptides in the blood, and the treatment of the disease using immunotherapy (vaccines).

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across a broad range of therapeutic areas: immunology, hepatology and intensive care, pulmonology, hematology, neurology and infectious diseases.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with over 390 across North America, Europe, Africa and the Middle East and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials, and for manufacturing

pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2022, Grifols' economic impact in its core countries of operation was EUR 9.6 billion. The company also generated 193,000 jobs, including indirect and induced.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [www.grifols.com](http://www.grifols.com).

## **MEDIA CONTACT:**

### **Media Press Office**

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 93 571 00 02

## **INVESTORS:**

### **Investors Relations Department & Sustainability**

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Tel. +34 93 571 02 21

---

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are "future projections and assumptions". Words and expressions such as "believe", "hope", "anticipate", "predict", "expect", "intend", "should", "will seek to achieve", "it is estimated", "future" and similar expressions, insofar as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group